SPDL1 and cancer: Finally, Oh et al. showed that elevated baseline sPD-L1 correlated with shorter PFS (median: 2.9 vs 6.3 months) and OS (median: 7.4 vs 13.3 months) and a lower disease control rate (58% vs 79%) in patients with a variety of cancers who were treated with nivolumab, pembrolizumab, ipilimumab, durvalumab, atezolizumab or combination therapy [82].